Articles
An analysis of outcomes for patients with treatment-naïve AML ineligible for intensive chemotherapy receiving either azacitidine or decitabine in the ASTRAL-1 study showed no significant differences in complete response (CR), overall CR, overall survival, or safety.
he SAL-DaunoDouble trial interim analysis suggests that, in patients with acute myeloid leukemia (AML) who respond well to a first 7+3 induction cycle of cytarabine plus anthracycline, it may be possible to omit a second induction cycle if deemed high-risk.
A retrospective analysis of patients with IDH-mutated AML revealed that NPM1mut is the best prognostic factor in patients who are IDH1mut and IDH2R140mut, making it a useful stratification factor for clinical trials.
The efficacy of 10-day decitabine plus venetoclax is comparable to intensive chemotherapy regimens as salvage therapy in younger patients with relapsed/refractory AML, and is an appropriate bridge to allogeneic stem-cell transplantation.
For patients with AML in the QUAZAR AML-001 trial who relapsed with 5% to 15% blasts on-study, an escalated 21-day CC-486 (oral azacitidine) dosing regimen was well-tolerated and restored remission in approximately 25% of patients.
A study comparing gilteritinib + azacitidine with azacitidine alone in patients with newly diagnosed, FLT3-mutated AML showed no new safety signals associated with gilteritinib. The safety cohort showed a composite response rate of 67% for gilteritinib + azacitidine.
Adjusted simulated treatment comparisons showed that the overall survival hazard ratios favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC numerically, but not statistically.
This study of 19 patients with IDH2-mutated acute myeloid leukemia indicates that a combination of the IDH2 inhibitor ivosidenib combined with venetoclax with or without azacitidine is effective and well-tolerated, warranting further study.
In this study, in patients with relapsed/refractory or secondary myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), decitabine + ipilimumab exhibited encouraging clinical activity, with an anticipated adverse event profile.
This phase 1b study demonstrated that adding the novel macrophage-targeting immunotherapy magrolimab to azacitidine is well-tolerated and effective for treating patients with AML who are unfit for chemotherapy.